ArticleBioinformatics (Oxford, England)2024
TargetSA: adaptive simulated annealing for target-specific drug design.
Article in Bioinformatics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Few-shot molecular property optimizationChemical science · 2026Article
- Task-specific pre-training for molecular property prediction.Briefings in bioinformatics · 2026Article
- Benchmarking Molecular Mutation Operators for Evolutionary Drug Design.International journal of molecular sciences · 2025Article
- Bridging chemical space and biological efficacy: advances and challenges in applying generative models in structural modification of natural products.Natural products and bioprospecting · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
motivationThe burgeoning field of target-specific drug design has attracted considerable attention, focusing on identifying compounds with high binding affinity toward specific target pockets. Nevertheless, existing target-specific deep generative models encounter notable challenges. Some models heavily rely on elaborate datasets and complicated training methodologies, while others neglect the multi-constraint optimization problem inherent in drug design, resulting in generated molecules with irrational structures or chemical properties.
resultsTo address these issues, we propose a novel framework (TargetSA) that leverages adaptive simulated annealing (SA) for target-specific molecular generation and multi-constraint optimization. The SA process explores the discrete structural space of molecules, progressively converging toward the optimal solution that fulfills the predefined objective. To propose novel compounds, we first predict promising editing positions based on historical experience, and then iteratively edit molecular graphs through four operations (insertion, replacement, deletion, and cyclization). Together, these operations collectively constitute a complete operation set, facilitating a thorough exploration of the drug-like space. Furthermore, we introduce a reversible sampling strategy to re-accept currently suboptimal solutions, greatly enhancing the generation quality. Empirical evaluations demonstrate that TargetSA achieves state-of-the-art performance in generating high-affinity molecules (average vina dock -9.09) while maintaining desirable chemical properties. AVAILABILITY AND IMPLEMENTATION: https://github.com/XueZhe-Zachary/TargetSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.